Table 1

Randomised trials comparing single-agent PARPi to monochemotherapy in patients with BRCA-mutated HER2-negative metastatic breast cancer

Study name (year)PARPiComparatorSettingPatients, n (PARPi/CT)HR+, n (%)
(PARPi/CT)
HR−, n (%)
(PARPi/CT)
Previous platinum, n (%) (PARPi/CT)
OlympiAD (2017)8 OlaparibMono-CT*Up to two prior CT regimens302 (205/97)103 (50.2)/49 (50.5)102 (49.8)/48 (49.5)60 (29.3)/26 (26.8)
EMBRACA (2017)13 TalazoparibMono-CT†Up to three prior CT regimen431 (287/144)157 (54.7)/84 (58.3)130 (45.3)/60 (41.7)46 (16.0)/30 (21.0)
  • *Eribulin, capecitabine or vinorelbine (according to physician’s choice).

  • †Eribulin, capecitabine, gemcitabine or vinorelbine (according to physician’s choice).

  • CT, chemotherapy; HR+, hormone receptor-positive; HR−, hormone receptor-negative; PARPi, PARP inhibitor.